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The blockade of metabotropic glutamate 5 (mGlu5) receptor has been reported to exert antidepressant
effects in several animal models. We previously reported that both ketamine and an mGlu5 receptor
antagonist exerted an effect in a novelty-suppressed feeding (NSF) test, and that the effect of ketamine
may be mediated through an a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor-
dependent increase in serotonergic transmission. However, the involvement of the serotonergic system
in the effect of mGlu5 receptor antagonists in the NSF test is not well understood. Therefore, we
examined the roles of the serotonergic system in the effect of an mGlu5 receptor antagonist, 6-methyl-2-
(phenylethynyl)pyridine hydrochloride (MPEP), in the NSF test in mice. The administration of MPEP
signiﬁcantly shortened the latency to feed, which was not attenuated by the AMPA receptor antagonist,
2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX). The effect of MPEP was
abolished by the tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA). Moreover, the
effect of MPEP was blocked by a serotonin (5-HT)2A/2C receptor antagonist, ritanserin, but not by a 5-HT1A
receptor antagonist, N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridynyl) cyclohexane-
carboxamide (WAY100635). These results suggest that the effect of an mGlu5 receptor antagonist may
be mediated by the serotonergic system, including the stimulation of the 5-HT2A/2C receptor, in an AMPA
receptor-independent manner in the NSF test.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Several lines of evidence have shown that modulation of the
glutamatergic system may be an effective treatment for depressive
symptoms, a hypothesis that has been supported by clinical obser-
vations using ketamine, a non-competitive N-methyl-D-aspartate
(NMDA) receptor antagonist. Indeed, ketamine has been reported to
exert rapid and sustained antidepressant effects in patients with
major depressive disorder, even in patients with treatment-
resistant depression (1e4), after a single injection as well as after
repeated injections (1,2,5). In a search of alternatives for ketamine,
which avoid undesirable side effects observed in ketamine therapy,
investigations on neural mechanisms underlying the antidepres-
sant effects of ketamine have been actively conducted. To date,: þ81 48 652 7254.
acological Society.
. Production and hosting by Elseketamine has beenproposed to exert antidepressant effects through
the stimulation of brain-derived neurotrophic factor (BDNF)-
mammalian target of rapamycin signaling and the blockade of
eukaryotic elongation factor 2 kinase, both of which are mediated
through the activation of the a-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA) receptor (6e8). In addition to
these mechanisms, which may lead to an increase in synaptic pro-
tein synthesis and spine density (for a review, see Ref. (6)), the
involvement of the serotonergic system in the actions of ketamine
has been suggested. For example, a positron emission tomography
study has revealed that treatment with high dose of ketamine
increased serotonin (5-HT)1B receptor binding in the nucleus
accumbens and the ventral pallidum in rhesus monkeys (9), and
ketamine increased extracellular 5-HT levels in the prefrontal cor-
tex in rats (10), with both mechanisms being mediated through
AMPA receptor stimulation.Moreover,we recently reported that the
depletion of 5-HT abolished the effect of ketamine in the novelty-
suppressed feeding (NSF) test and that the stimulation of thevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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stimulationmay be involved in the effects of ketamine in thismodel
(11). Thus, these ﬁndings indicate that the AMPA receptor-mediated
activation of serotonergic systems may be involved in the antide-
pressant effect of ketamine.
Among the glutamate receptors, the metabotropic glutamate 5
(mGlu5) receptor has been reported to have roles in depression.
Indeed, mGlu5 receptor levels are reportedly decreased in certain
brain regions of depressed patients and rodent models of depres-
sion (12e14). In addition, mGlu5 receptor antagonists, such as
2-methyl-6-(phenylethynyl)-pyridine (MPEP), 3-[(2-methyl-1,3-
thiazol-4-yl)ethynyl]-pyridine (MTEP), and (4-diﬂuoromethoxy-3-
(pyridine-2-ylethynyl)phenyl)5H-pyrrolo[3,4-b]pyridine-6(7H)-yl
methanone (GRN-529), reportedly exhibited antidepressant effects
in several animal models of depression (15e18), raising the possi-
bility that mGlu5 receptor blockade may be a useful approach for
treating depression. The neural mechanisms underlying the anti-
depressant effects of mGlu5 receptor antagonists have not been
fully elucidated, although interactions with NMDA receptor and
BDNF signaling have been suggested (for a review, see Ref. (19)).
Recently, the involvement of serotonergic systems in the antide-
pressant and anxiolytic effects of mGlu5 receptor antagonists has
been reported. The antidepressant effect of MTEP was blocked by
pretreatment with a tryptophan hydroxylase inhibitor, para-
chlorophenylalanine (PCPA), in the tail suspension test (TST) (20),
and both the antidepressant and anxiolytic effects of MTEP were
also blocked by a 5-HT2A/2C receptor antagonist (20,21). Addition-
ally, MTEP increased the extracellular 5-HT levels in the prefrontal
cortex in rats (21). Thus, the antidepressant effect of mGlu5 re-
ceptor antagonists may mediate an increase in serotonergic sys-
tems, as observed for ketamine.
We recently reported that an mGlu5 receptor antagonist
exhibited both acute and sustained effects in the NSF test (22), a
model which measures latency to feed in an aversive environment
and is sensitive to chronic but not acute treatment with antide-
pressants, and acute and sustained effects were also observed with
ketamine (23). Using this model, we investigated the roles of the
serotonergic system in the action of ketamine, as described above.
Therefore, the NSF test is likely to be a useful model for comparing
the neural mechanisms of an mGlu5 receptor antagonist, particu-
larly the roles of the serotonergic system, with those of ketamine.
However, the involvement of the serotonergic system in the action
of an mGlu5 receptor antagonist in the NSF test has not been
investigated.
In the present study, we ﬁrst investigated the involvement of the
serotonergic system in the effect of an mGlu5 receptor antagonist,
MPEP, in the NSF test by depleting 5-HT with PCPA. Then, we
investigated the roles of 5-HT receptor subtypes using the respec-
tive antagonists. Moreover, we investigated the involvement of
AMPA receptor stimulation in the action of an mGlu5 receptor
antagonist, since AMPA receptor stimulation reportedly mediates
the enhancement of the serotonergic system by ketamine.
2. Materials and methods
2.1. Animals and housing
Nine-week-old male C57BL/6J mice (Charles River Laboratories,
Yokohama) were used for all the experiments. The animals were
maintained under a controlled temperature (23 ± 3 C) and hu-
midity (50 ± 20%) with a 12-h light/dark cycle (lights on at 7:00
a.m.). Food and water were provided ad libitum, except for the
deprivation of food for 24 h prior to the NSF test. All the studies
were performed according to the Taisho Pharmaceutical Co., Ltd.
Animal Care Committee and met the Japanese ExperimentalAnimal Research Association standards, as deﬁned in the Guide-
lines for Animal Experiments (1987).
2.2. Drug administration
MPEP (SigmaeAldrich Co., St. Louis, MO, USA) was dissolved in
0.5% methylcellulose (0.5% MC). 2,3-Dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-Sulfonamide (NBQX) (Tocris
Cookson Ltd., Bristol, UK) was suspended in saline. PCPA (Wako
Pure Chemical Industries, Ltd, Osaka) and ritanserin (Sigma-
eAldrich Co., St. Louis, MO, USA) were suspended in 0.5% MC. N-{2-
[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridynyl)cyclo-
hexane-carboxamide (WAY100635) (SigmaeAldrich Co., St. Louis,
MO, USA) was dissolved in saline. MPEP (3 mg/kg) was adminis-
tered intraperitoneally (i.p.) 60min prior to the test. NBQX (1, 3, and
10mg/kg) andWAY100635 (0.3, 1, and 3mg/kg) were administered
subcutaneously (s.c.) at 65 min and 90 min prior to the test,
respectively. Ritanserin (0.125, 0.25, and 0.5 mg/kg) was adminis-
tered i.p. 90 min prior to the test. PCPA (300 mg/kg) was admin-
istered i.p. twice daily (at 7:00e11:00 and 16:00e19:00) for 3
consecutive days, and the tests were conducted 18 h after the ﬁnal
administration. All the drugs were injected at a volume of 10 mL/kg
body weight. The doses for the systemic administration of MPEP,
NBQX, PCPA, WAY100635, and ritanserin were selected based on
previous studies (11,22).
2.3. Novelty-suppressed feeding test in mice
The NSF test was performed during a 5-min period, as
described previously (11). Of note, we previously reported that
ﬂuvoxamine exerted an effect following treatment for 28 days in
the NSF test, while MPEP exerted an effect after single treatment
under the same condition (22). The mice were weighed, and all
food was removed from their cages. Water continued to be pro-
vided ad libitum. Approximately 24 h after the removal of the
food, the mice were transferred to the testing room, placed in a
clean holding cage, and allowed to habituate for 30 min. The
testing apparatus consisted of a Plexiglas box (45  45  20 cm) in
an illuminated (approximately 1000 lux), soundproofed box. The
ﬂoor of the box was covered with 1 cm of wooden bedding. A small
piece of mouse chow was placed in the center of the box on a
white circular ﬁlter paper (11 cm in diameter). Each subject was
placed in the corner of the testing arena, and the time until the
ﬁrst feeding episode was recorded. Immediately after the mouse
began to eat the chow, the tested animal was placed alone in its
home cage with a weighed piece of chow for 5 min. At the end of
this period, the amount of food consumed was determined by
weighing the piece of chow. After all the mice from a single cage
had been tested, the mice were returned to their home cage with
food and water provided ad libitum. NBQX, PCPA, WAY100635,
and ritanserin did not affect the latency to feed in the NSF test at
the doses used in the present study (11). None of the treatments
affected the amount of food consumed at doses used in the test
(data not shown).
2.4. Statistical analysis
The results were expressed as the mean ± S.E.M. Statistical
signiﬁcance was determined using a one-way analysis of variance
(ANOVA) or a two-way ANOVA, followed by the Student's t-test and
the Dunnett's test or the LSD post-hoc test for comparing the
treated group with a control group and multi-group comparisons,
respectively. Statistical differences between the two sets of groups
were determined using the Student's t-test. A value of P <0.05 was
considered statistically signiﬁcant.
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Fig. 3. Effect of a 5-HT2A/2C receptor antagonist on the action of MPEP in the NSF test in
mice. MPEP (3 mg/kg i.p.) was administered 60 min prior to the test. Ritanserin (0.125,
0.25 and 0.5 mg/kg i.p.) was administered 90 min prior to the test. Values indicate the
mean ± S.E.M. (n ¼ 12). **P < 0.01 compared with 0.5% MC-treated vehicle, ##P < 0.01
compared with 0.5% MC-treated MPEP (Dunnett's test).
0
40
80
120
160
200
240
280
0.5% MC PCPA
L
at
en
cy
 to
 fe
ed
 (s
ec
.)
**
□ Vehicle    ■MPEP
##
Fig. 1. Effect of 5-HT depletion on the action of MPEP in the NSF test in mice. MPEP
(3 mg/kg i.p.) was administered 60 min prior to the test. PCPA (300 mg/kg i.p.) was
administered twice daily for 3 consecutive days until the day before the test. Values
indicate the mean ± S.E.M. (n ¼ 10e12). **P < 0.01 compared with 0.5% MC-treated
vehicle, ##P < 0.01 compared with 0.5% MC-treated MPEP (LSD post-hoc test).
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3.1. Effect of 5-HT depletion on the action of MPEP in the NSF test
MPEP signiﬁcantly reduced the latency period until feeding in
the NSF test [F(3,40) ¼ 4.46, P < 0.01] (Fig. 1). The decrease in the
latency to feed induced by MPEP (3 mg/kg i.p.) was blocked by
pretreatment with PCPA (300 mg/kg i.p. twice daily for 3 days)
[MPEP, F(1,40) ¼ 5.46, P < 0.05; PCPA, F(1,40) ¼ 3.07, P ¼ 0.09;
interaction, F(1,40) ¼ 4.87, P < 0.05] (Fig. 1). Pretreatment with
PCPA itself did not affect the latency to feed (Fig. 1).
3.2. Effect of a 5-HT1A receptor antagonist on the action of MPEP in
the NSF test
MPEP signiﬁcantly reduced the latency period until feeding in
the NSF test [F(1,22) ¼ 8.25, P < 0.01] (Fig. 2). The decrease in the
latency to feed induced by MPEP (3 mg/kg i.p.) was not blocked by
pretreatment with a 5-HT1A receptor antagonist, WAY100635 (0.3,
1, and 3 mg/kg s.c.) [F(3,43) ¼ 0.06, P ¼ 0.98] (Fig. 2).
3.3. Effect of a 5-HT2A/2C receptor antagonist on the action of MPEP
in the NSF test
MPEP signiﬁcantly reduced the latency period until feeding in
the NSF test [F(1,22) ¼ 12.36, P < 0.01] (Fig. 3). The decrease in the0
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Fig. 2. Effectof a 5-HT1A receptorantagoniston theactionofMPEP in theNSF test inmice.
MPEP (3 mg/kg i.p.) was administered 60 min prior to the test. WAY100635 (0.3, 1 and
3mg/kg s.c.)was administered 90minprior to the test. Values indicate themean± S.E.M.
(n ¼ 11e12). **P < 0.01 compared with saline-treated vehicle (Student's t-test).latency to feed induced by MPEP (3 mg/kg i.p.) was blocked by
pretreatment with a 5-HT2A/2C receptor antagonist, ritanserin
(0.5 mg/kg i.p.) [F(3,44) ¼ 3.86, P < 0.05] (Fig. 3).
3.4. Effect of an AMPA receptor antagonist on the action of MPEP in
the NSF test
MPEP signiﬁcantly reduced the latency period until feeding in
the NSF test [F(1,21) ¼ 14.54, P < 0.01] (Fig. 4). The decrease in the
latency to feed induced by MPEP (3 mg/kg i.p.) was not blocked by
pretreatment with an AMPA receptor antagonist, NBQX (1, 3 and
10 mg/kg s.c.) [F(3,44) ¼ 0.59, P ¼ 0.63] (Fig. 4).
4. Discussion
In the present study, we demonstrated that, similar to ketamine,
an mGlu5 receptor antagonist exerted its effect through the sero-
tonergic system in the NSF test, although the mechanisms of the
involvement of the serotonergic system were different.
The main purpose of the present study was to investigate the
involvement of the serotonergic system in the effect of MPEP in the
NSF test. In the present study, the effect of MPEP was blocked by0
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Fig. 4. Effect of an AMPA receptor antagonist on the action of MPEP in the NSF test in
mice. MPEP (3 mg/kg i.p.) was administered 60 min prior to the test. NBQX (1, 3 and
10 mg/kg s.c.) was administered 65 min prior to the test. Values indicate the
mean ± S.E.M. (n ¼ 11e12). **P < 0.01 compared with saline-treated vehicle (Student's
t-test)).
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gesting that serotonergic transmission plays a role in the effect of
the mGlu5 receptor antagonist in the NSF test. It should be noted
that this is the ﬁrst report to demonstrate the involvement of
serotonergic transmission in the effect of an mGlu5 receptor
antagonist in the NSF test. Previously, we demonstrated that
treatment with PCPA (300 mg/kg twice daily for 3 days) caused a
74.8% reduction in the 5-HT content in the frontal cortex in mice,
compared with a vehicle-treated group, and abolished the head-
twitch response induced by a 5-HT release-promoting agent, PCA
(11). Therefore, the treatment condition with PCPA used in this
study is sufﬁcient for the pharmacological depletion of 5-HT in
mouse brain. This ﬁnding is consistent with previous reports that
the antidepressant-like effect of MTEP was attenuated by PCPA
treatment in the TST (20), indicating that serotonergic transmission
may play a key role in the actions of mGlu5 receptor antagonists
across animal models.
Next, we investigated the involvement of the 5-HT receptor
subtype in the effect of MPEP in the NSF test. 5-HT1A and 5-HT2A/2C
receptors were investigated in the present study because these
receptors play important roles in the antidepressant and anxiolytic-
like effects of agents (24,25). We found that the effect of MPEP was
blocked by a 5-HT2A/2C receptor antagonist, ritanserin, but not by a
5-HT1A receptor antagonist, WAY100635, in the NSF test. These
results suggest that the stimulation of the 5-HT2A/2C receptor, but
not the 5-HT1A receptor, mediates the effect of MPEP in the NSF test.
These ﬁndings are consistent with previous reports that the anti-
depressant and anxiolytic effects of MTEP were attenuated by
ritanserin but not WAY100635 in the TST and Vogel conﬂict
drinking test (20,21). Given that both MPEP and MTEP do not have
activities at 5-HT receptors and mGlu5 receptor antagonists have
been reported to increase 5-HT release in the prefrontal cortex and
hippocampus (21,26,27), the blockade of mGlu5 receptors may
indirectly stimulate the 5-HT2A/2C receptor through an increase in
5-HT release, leading to the antidepressant/anxiolytic effects in
animal models, including the NSF test.
Although the effects of both an mGlu5 receptor antagonist and
ketamine in the NSF test are mediated through serotonergic
transmission, the mechanism of the mGlu5 receptor antagonist
differs from that of ketamine, since we previously reported that the
5-HT1A receptor, but not the 5-HT2A/2C receptor, is involved in the
effect of ketamine (11). Ketamine reportedly increases 5-HT release
via the stimulation of the AMPA receptor (10) in the prefrontal
cortex, which may lead to the stimulation of the postsynaptic 5-
HT1A receptor and its subsequent effects. Interestingly, a clear
distinction existed between the mGlu5 receptor antagonist and
ketaminewith regard to the role of the effects of the AMPA receptor
in the NSF test. While the effect of MPEP in the NSF was not
attenuated by NBQX in the present study, we reported that the
effect of ketamine was blocked by NBQX in the same paradigm.
Therefore, the mGlu5 receptor antagonist may increase 5-HT
release via a different neural mechanism from that of ketamine,
i.e., an AMPA receptor-independent mechanism, which may
explain the involvement of distinct 5-HT receptor subtypes in the
effects in the NSF test.
The neural mechanism of 5-HT release and the activation of the
5-HT2A/2C receptor induced by an mGlu5 receptor antagonist in
the NSF test remain to be elucidated. Treatment with MTEP
reportedly increases 5-HT release without elevating 5-HTIAA in
the prefrontal cortex in rats, indicating that the blockade of the
mGlu5 receptor may inhibit the 5-HT transporter to increase 5-HT
release (21). However, Heidbreder et al. (2003) reported that
MPEP had a moderate afﬁnity for the norepinephrine (NE) trans-
porter, but not for the 5-HT transporter, as evaluated using radi-
oligand binding assays (26). Moreover, 5-HT transporter inhibitorsreportedly do not exert an effect after acute treatment in the NSF
test (28), which is in accord with our previous ﬁnding (22).
Therefore, it is unlikely that an mGlu5 receptor antagonist in-
creases 5-HT release by inhibiting the 5-HT transporter. Of note, a
previous study showed that gene deletion of the mGlu5 receptor
in mice increased the behavioral response to a 5-HT2A receptor
agonist, suggesting that blockade of the mGlu5 receptor may
enhance the sensitivity to the 5-HT2A receptor (29). Moreover, 5-
HT2 receptors are positioned on GABAergic neurons (30), and
the stimulation of 5-HT2 receptors increases GABA release in the
prefrontal cortex (31). Given that the GABAergic system is known
to be disrupted in depressed patients (for a review, see Ref. (32)), it
is intriguing to speculate that regulation of the GABAergic system
via the 5-HT2 receptor may be involved in the antidepressant
effect of mGlu5 receptor antagonists.
The present study has a notable limitation. The speciﬁcity of the
mGlu5 receptor antagonist, MPEP was not optimal, as it also in-
hibits the NMDA receptor and NE transporter (26,33) as well as
acting as a positive allosteric modulator of the mGlu4 receptor (34).
However, MPEP acts on the above-mentioned receptors and
transporter at a concentration more than 1000 times higher than
that blocks the mGlu5 receptor (an IC50 value of 36 nM) (35), and
MPEP did not exhibit an antidepressant-like effect in mGlu5
receptor-knockout mice in the forced swimming test (36). Thus, the
effect of MPEP at a dose 3mg/kg canmost likely be attributed to the
blockade of the mGlu5 receptor.
In conclusion, we have provided the ﬁrst evidence that the effect
of an mGlu5 receptor antagonist may be mediated through sero-
tonergic transmission, presumably an increase in 5-HT release and
the subsequent stimulation of 5-HT2A/2C receptor in the NSF test,
and that the neural mechanism differs from that of ketamine.
Further investigation of the neural mechanisms of mGlu5 receptor
antagonists and comparisons of the mechanisms with those of
ketamine may warrant the clinical efﬁcacy of mGlu5 receptor an-
tagonists for the treatment of depression and anxiety disorders.Conﬂicts of interest
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